Rapid and efficient development of drug candidates sits top of mind for pharmaceutical companies with funding constraints looking to accelerate timelines. Unfortunately, many early drug candidates demonstrate poor oral absorption properties, which can make it challenging to achieve target pharmacokinetic profiles. Without up-front knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs.
PBPK (physiologically based pharmacokinetic) studies can be conducted on rapid timelines with minimal amounts of API. The findings help drug sponsors make informed decisions about the priorities of their drug development process, gain improved context for understanding poor absorption, and implement risk mitigation strategies early on. Ultimately, PBPK modeling helps save time and money by reducing the need for reformulation or repeated in vivo studies.
Read the white paper from Lonza Small Molecules and Simulations Plus for more.